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Abstract
Objectives To assess the costs of diagnostic workup and sur-
gery of three strategies for patients with colorectal cancer
liver-metastases (CRCLM): gadoxetic-acid-enhanced MRI
(Gd-EOB-DTPA-MRI), MRI with extracellular contrast-
media (ECCM-MRI) or contrast-enhanced MDCT (CE-
MDCT).
Methods The within-trial cost evaluation was modelled as a
decision-tree to calculate the cost of diagnosis and surgery.
The model used clinical outcomes and resource utilization
data from a prospective randomized multicentre study.
Analyses were performed for the 354-patient safety popula-
tion from eight participating countries.
Results The diagnostic workup cost using Gd-EOB-DTPA-
MRI upfront resulted in savings compared to ECCM-MRI in
all countries except Thailand (difference <2 %). Compared to
CE-MDCT, initial imaging with Gd-EOB-DTPA-MRI was
less costly in all countries except Korea and Spain (differences
4 and 8 %, respectively). Significantly more patients in the
Gd-EOB-DTPA-MRI group were eligible for surgery (39.3 %
(48/122) vs. 31.0 % (36/116) and 26.7 % (31/116) for ECCM-
MRI and CE-MDCT, respectively), allowing more patients to
undergo potentially curative surgery, but resulting in higher
treatment costs for the strategy starting with Gd-EOB-DTPA-
MRI.
Conclusions The benefits of Gd-EOB-DTPA-MRI due to less
additional imaging and similar diagnostic workup costs in the
three groups suggest that Gd-EOB-DTPA-MRI should be the
preferred initial imaging procedure to evaluate hepatic resect-
ability in patients with CRCLM.
Key Points
•Diagnostic imaging cost to evaluate resectability was similar
among the groups
• Cost for imaging was rather small compared to the cost of
surgery
• Significantly more patients in the Gd-EOB-DTPA-MRI arm
were eligible for surgery
•Gd-EOB-DTPA-MRI is recommended for evaluating hepatic
resectability in patients with CRCLM
Keywords Cost . Economic evaluation . Liver imaging .
Magnetic resonance imaging . Contrast agents
Introduction
Globally, colorectal cancer (CRC) is one of the leading causes
of tumour-associated deaths [1]. A major determinant of out-
come is the extent of disease. Patients with metastatic (Stage
IV) disease have a 5-year survival rate of 12 % compared with
90 % for Stage I/II and 70 % for Stage III disease [2]. Twenty-
five to 50 % of patients with CRC present with liver
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metastases, either synchronous or metachronous (at a later
stage), after the initial diagnosis of the primary tumour [3].
Surgery can achieve cure in both hepatic and extrahepatic
metastatic disease, provided that all of the tumour can be
resected. Overall 5-year survival ranges between 16 % and
74 % after liver resection for hepatic colorectal metastasis
[4]. Hepatic recurrence can be expected in 50–60% of patients
with hepatic metastases [5–7].
Surgical strategy in patients scheduled for liver resection is
based on pre-operative imaging with a variety of modalities,
including computed tomography (CT), magnetic resonance
imaging (MRI), ultrasound (US) and positron emission to-
mography (PET) or PET-CT. The final assessment of the ex-
tent of the disease, however, is made during the operation by
surgical exploration of the liver and intra-operative ultra-
sound. Deviation from the pre-operative surgical plan due to
additional intra-operative findings is undesirable and can po-
tentially lead to increased costs.
MRI has been demonstrated to be the best imaging method
for detection and characterization of focal liver lesions [8–10].
The detection and characterization capabilities of MRI can be
enhanced further by using hepatobiliary contrast agents like
gadoxetic-acid (gadolinium ethoxybenzyl-diethylenetriamine-
penta-acetate; Gd-EOB-DTPA) [11–18]. The VALUE study, a
prospective, randomized trial that compared Gd-EOB-DTPA-
MRI, MRI with extracellular contrast media (ECCM-MRI) and
contrast-enhanced multiple detector CT (CE-MDCT) for hepat-
ic staging of patients with suspected or confirmed
metachronous CRC-liver metastases (CRCLM), has recently
been published [19]. The VALUE study showed that patients
randomized to initial diagnostic imaging with Gd-EOB-DTPA-
MRI needed significantly fewer additional imaging procedures
for a confident diagnosis and treatment decision, compared to
those randomized to ECCM-MRI or CE-MDCT as initial im-
aging modality. Furthermore, Gd-EOB-DTPA-MRI imaging
yielded a significantly higher confidence in the diagnosis and
treatment plan compared to the other two modalities. The in-
formation provided by Gd-EOB-DTPA-MRI resulted in a de-
creased number of patients with intra-operative modifications
of the surgical plan in patients undergoing liver resection.
The economic implications of the medical benefits of initial
imaging with Gd-EOB-DTPA-MRI observed for patients in
this clinical scenario, however, remain to be determined.
Thus, the purpose of this within-trial cost evaluation of the
VALUE study was to assess the comparative costs of diagnos-
tic workup and surgery of the three strategies; i.e. initial
Fig. 1 Outline of the cost-
evaluation model
Table 1 Diagnostic workup, transition probabilities, number of patients and percentage of those who received a first imaging in each group
Initial imaging
CE-MDCT ECCM-MRI Gd-EOB-DTPA-MRI
Further imaging required? No further imaging 70 (60.3 %) 95 (81.9 %) 122 (100.0 %)
Further imaging required 46 (39.7 %) 21 (18.1 %) 0 (0.0 %)
Second imaging with CE-CT 0 (0.0 %) 0 (0.0 %) -
Second imaging with ECCM-MRI 1 (2.2 %) 0 (0.0 %) -
Second imaging with Gd-EOB-DTPA-MRI 45 (97.8 %) 21 (100.0 %) -
Total 116 (100.0 %) 116 (100.0 %) 122 (100.0 %)
CE-MDCT contrast-enhanced MDCT, ECCM-MRI MRI with extracellular contrast-media, Gd-EOB-DTPA-MRI gadoxetic-acid-enhanced MRI, MRI
magnetic resonance imaging, CT computed tomography, MDCT multiple detector CT
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imaging with Gd-EOB-DTPA-MRI, ECCM-MRI or CE-
MDCT in patients with suspected CRCLM.
Materials and methods
This within-trial cost evaluation of the VALUE study was based
on data for 360 patients with known or suspected metachronous
liver metastases secondary to colorectal cancer whowere sched-
uled for further contrast-enhanced tomographic imaging, who
were randomized to one of the three initial imaging techniques.
The randomization list was developed by a biometrician. The
final randomization code was generated using the validated pro-
gram RANDOM as 1 : 1 : 1 randomization (block size 6). The
randomization list included the randomization codes, patient
identifier and assigned imaging modality. The randomization
information was provided in sealed envelopes that were kept
securely in the radiology department at each study site. Patients
were recruited from eight countries (Switzerland N=3; Sweden
N=4; Italy N=13; Spain N=16; Thailand N=62; Austria
N=77, Germany N=83 and Korea N=102). The study was
conducted in accordance with the ethical principles stated in the
Declaration of Helsinki and the International Conference on
Harmonisation Good Clinical Practice guidelines, following ap-
proval by relevant ethics committees/institutional review boards
at the participating centres. All patients gave their written in-
formed consent to participate in the study.
Six patients did not receive any treatment or contrast agent
in the study and were dropouts (screening failures). All pa-
tients who received any amount of contrast medium were
included in the safety population (N=354). Population char-
acteristics as well as safety analyses were performed using all
available data from those patients. All patients who received a
contrast medium, for whom the primary parameter was avail-
able and who had no major protocol deviation, were included
in the efficacy population (N=342).
Whenever possible, the analyses in this manuscript were
made on the safety population. Some data presented in this
paper differ slightly from those in the article describing the
clinical results of the VALUE study [19], where most of the
analyses were performed on the efficacy population.
The safety population was as follows: 122 had initial imag-
ing with Gd-EOB-DTPA-MRI, 116 with ECCM-MRI and 116
with CE-MDCT. For some homogeneity analyses, however, the
efficacy population consisting of 342 patients was used since
some of the variables tested were only measured for those pa-
tients who completed the study. This trial-based cost analysis
was programmed as a decision-tree (using TreeAge Pro 2009),
designed to mirror the outline of a model-based health-econom-
ic approach published previously [20] and populated with actual
clinical data from the VALUE study [19]. An overview of the
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Transition probabilities
After the initial imaging procedure, the first consensus meet-
ing consisting of the local investigators (liver surgeon and
radiologist, and in some instances also an oncologist accord-
ing to local practice) was held to decide whether a confident
treatment decision could be made or if further imaging was
required to come to a therapy decision. The consensus group
was aware of the intent of the study and that a health-
economic evaluation was planned after publishing the primary
study results. If further imaging was required, the interdisci-
plinary team (as specified above) was free to choose one of the
two remaining imaging modalities, followed by another inter-
disciplinary team meeting. After pre-treatment imaging (one
or two modalities), a treatment plan was drafted with patients
with potentially operable disease being referred for surgical
intervention. In patients deemed operable, a detailed operation
plan was drafted. The probabilities for ‘further imaging re-
quired’ were calculated from the patient-level data as the pro-
portion of patients who required a second imaging procedure
(Table 1).
In total, 115 patients were assessed as being primarily re-
sectable, i.e. could be rendered tumour free by one operative
intervention (surgery with/without concomitant local ablation)
without the necessity of pre-operative tumour or volume ma-
nipulation by down-staging chemotherapy or portal-vein em-
bolization. During surgery, it was documented whether the
operation resulted in liver resection and whether the pre-
operative surgical plan was executed unchanged or modified
due to additional intra-operative findings. Among patients for
whom the surgical plan was modified during surgery, the
probability of having a longer intervention was estimated
and the difference in surgery time due to modification of the
surgical plan was recorded. The difference in surgery timewas
intended to judge the estimated amount of additional planning
time, and not the increase in the procedural time itself.
Finally, the probabilities of modification of the surgical
plan resulting in no resection during surgery (i.e. undergoing
non-therapeutic intervention, hereafter referred to as ‘unnec-
essary surgery’) were estimated from the patient-level
VALUE data. These transition probabilities are presented in
Table 2. Transition probabilities and resource use were always
estimated for the pooled patient population, and not stratified
by country. As such, the sample size was the same for all
countries, so that the differences in patients included per coun-
try did not have an effect on the country-specific evaluation
later on.
Resource utilization and cost
A payer perspective was adopted for the cost analysis with
Germany as the base case. Analyses were then conducted
for the remaining countries participating in the trial: Austria,
Italy, Korea, Spain, Sweden, Switzerland and Thailand. Unit
costs collected for these countries were multiplied by the re-
source utilization of the pooled population for a cross-country
comparison (unit costs and references are presented in
Supplemental Table 1).
The VALUE data contained the following detailed
patient-level information on resource utilization: (a) con-
trast agents used for the imaging, (b) length of surgery,
(c) estimated additional length of surgery in case of a
modified surgical plan, (d) number of days of intensive
care following surgery and (e) number of days of stan-
dard in-hospital care following surgery.
The total cost of diagnostic workup in each group was
calculated as: [cost of imaging procedure without contrast +
cost of contrast media expressed as the weighted average of
substances used in the VALUE trial + cost of a consensus
meeting(s)]. The list of contrast agents, their weights and costs
are presented in Supplemental Table 1. The cost of the con-
sensus meeting was estimated in consultation with clinical
experts in each country, following local practices. In some
countries, it consisted of a surgeon and radiologist while in
others an oncologist was also involved (Supplemental
Table 2). The aim of this approachwas to obtain cost estimates
mirroring the VALUE trial that would be applicable to each
country’s clinical routines.
The cost of planned surgery was calculated as: [surgery
time*cost per minute of surgery under anaesthesia + days in
intensive care*cost per day in intensive care + days in standard
care*cost per day in standard care]. The additional cost of
prolonged surgery was calculated as: [mean additional length
of surgery *cost per minute of surgery under anaesthesia]. The
resource use (minutes of surgery and days in hospital) was
calculated as the total means across all imaging sequences.
Table 3 Resource utilization for




Average number of minutes of surgery per patient (range) 240 (88–700) 163 (128–205)
Average number of hospitalization days in standard care
per patient (range)
12.4 (0–104) 21.3 (10–38)
Average number of hospitalization days in intensive care
per patient (range)
2.6 (0–42) 7.3 (0–17)
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Table 4 Costs of diagnostic workup and surgery, and cost difference in the different countries (expected per-patient cost in € 2013)
Cost item Austria Germany Italy Korea Spain Sweden Switzerland Thailand
Cost breakdown of the strategy
starting with Gd-EOB-DTPA-MRI
Cost of diagnostic workup 337 403 267 276 692 1636 564 381
Cost of planned resection 6,041 3,019 7,634 2,117 7,131 6,914 7,080 4,683
Additional cost due to
modified surgical procedures
18 18 149 14 144 53 59 140
Cost of unnecessary surgery 265 129 195 84 175 284 263 71
Total cost 6,661 3,568 8,244 2,491 8,142 8,886 7,966 5,275
Total cost excluding cost of
planned resection
620 549 610 374 1,011 1,972 886 592
Cost breakdown of the strategy
starting with CE-MDCT
Cost of diagnostic workup 603 421 379 266 640 2,259 657 400
Cost of planned resection 4,196 2,097 5,303 1,471 4,954 4,803 4,919 3,253
Additional cost due to
modified surgical procedures
13 13 112 11 108 40 44 105
Cost of unnecessary surgery 0 0 0 0 0 0 0 0
Total cost 4,813 2,532 5,794 1,747 5,702 7,102 5620 3,759
Total cost excluding cost of
planned resection
617 435 491 276 748 2,299 701 506
Cost breakdown of the strategy
starting with ECCM-MRI
Cost of diagnostic workup 405 405 377 294 723 2,082 595 374
Cost of planned resection 4,600 2,299 5,813 1,612 5,431 5,265 5,392 3,566
Additional cost due to
modified surgical procedures
13 13 111 11 108 40 44 105
Cost of unnecessary surgery 555 269 407 176 365 593 549 147
Total cost 5,573 2,986 6,709 2,092 6,627 7,980 6,580 4,193
Total cost excluding cost of
planned resection
973 687 896 480 1,196 2,715 1,188 627
Comparison of cost of diagnostic workup Gd-EOB-DTPA-MRI minus
CE-MDCT
−266 −18 −112 10 52 −623 −93 -19
Gd-EOB-DTPA-MRI minus
ECCM-MRI
−68 −2 −110 −18 −31 −446 −31 7
Comparison of costs of planned resection Gd-EOB-DTPA-MRI minus
CE-MDCT
1,845 922 2,331 646 2,177 2,111 2,161 1,430
Gd-EOB-DTPA-MRI minus
ECCM-MRI
1,441 720 1,821 505 1,700 1,649 1,688 1,117
Comparison of additional costs
due to modified procedures
Gd-EOB-DTPA-MRI minus
CE-MDCT
5 5 37 3 36 13 15 35
Gd-EOB-DTPA-MRI minus
ECCM-MRI
5 5 38 3 36 13 15 35




265 129 195 84 175 284 263 71
Gd-EOB-DTPA-MRI minus
ECCM-MRI
−290 −140 −212 −92 −190 −309 −286 −76




2,115 1,056 2,563 733 2,388 2,408 2,439 1,536
Gd-EOB-DTPA-MRI minus
ECCM-MRI
1,156 585 1,647 416 1,546 1,353 1,417 1,076
Comparison of total costs Gd-EOB-DTPA-MRI minus
CE-MDCT
1,848 1036 2,450 744 2,440 1,784 2,346 1,516
Gd-EOB-DTPA-MRI minus
ECCM-MRI
1,088 582 1,535 399 1,515 906 1,386 1,082




3 114 119 98 263 −327 185 86
Gd-EOB-DTPA-MRI minus
ECCM-MRI
−353 −138 −286 −106 −185 −743 −302 −35
CE contrast-enhanced, CE-MDCT contrast-enhanced MDCT, ECCM-MRIMRI with extracellular contrast-media,Gd-EOB-DTPA-MRI gadoxetic-acid-
enhanced MRI, MRI magnetic resonance imaging, CT computed tomography, MDCT multiple detector CT
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The resource use was calculated separately for resected and
unresected patients (Table 3), based on the assumption that the
length of surgery and the days spent in hospital would be
different for patients with surgery but without any resection
and those with surgery and liver metastases resection.
Statistical analysis
Homogeneity chi-square tests were performed to test for ran-
domization bias with regard to age and disease severity as
measured by (a) presence of non-assessable lesions, (b) pres-
ence of assessable lesions, (c) number of affected segments,
and (d) total number of lesions. Following cost estimation,
one-way sensitivity analyses were performed by systematical-
ly varying one input value at a time (values [prices and prob-
abilities] were varied by ±5 %) and observing the impact of
that change on the results. Sensitivity analyses were per-
formed on the base case, i.e. using 2013 German unit costs.
In addition, three alternate scenarios were included.
The first alternative scenario was ‘No avoided surgery due
to missing additional information of second imaging in the
CE-MDCT group’. This scenario was chosen based on five
patients in the CE-MDCT group, for whom unnecessary sur-
gery was avoided as the result of a secondary imaging (four
cases with Gd-EOB-DTPA-MRI group and one case with
ECCM-MRI). The second scenario was ‘Unresectable pa-
tients recognized before surgery’. In this scenario, two patients
who were unresectable because of extrahepatic disease burden
were assumed to have been classified as unresectable from the
beginning (a second advanced primary tumour of the sigmoid
colon in a patient in the Gd-EOB-DTPA-MRI group and ex-
trahepatic growth and peritoneal metastases in a patient in the
ECCM-MRI group). In the third scenario, it was assumed that
the probability for selection for surgery was equal in all three
groups (32.5 %; representative of the 115 patients out of 354
in the whole dataset who were selected for surgery). This third
scenario corrects for the impact of more patients being select-
ed for surgery in the Gd-EOB-DTPA-MRI group relative to
the other two groups.
All statistical analyses were done in Stata version 10.0.
Results
Homogeneity analysis
The imaging strategy starting with Gd-EOB-DTPA-MRI de-
tected CRCLM in significantly more patients compared to
ECCM-MRI or CE-MDCT (85/118 (70.0 %), 72/112
(64.3 %) and 66/112 (58.9 %), respectively [P < 0.0001,
Fisher’s exact test (pairwise)]). Moreover, more patients diag-
nosed with liver metastases in the Gd-EOB-DTPA-MRI group
were assessed as eligible for surgery (39.3 % (48/122) vs.
31 % (36/116) and 26.7 % (31/116) in the ECCM-MRI and
CE-MDCT groups, respectively). The results of the homoge-
neity analysis are presented in Supplemental Table 3: random-
ization bias between the groups with regard to patients’ age or
disease severity as measured by the different proxies evaluat-
ed could be ruled out between the three groups.
Cost of diagnostic workup
Costs for diagnostic workup and surgery for the three strate-
gies are summarized in Table 4 and Fig. 2. Initial imaging with
Gd-EOB-DTPA-MRI resulted in cost savings compared to
ECCM-MRI in all countries except Thailand where the differ-
ence was less than 2 %. Compared to CE-MDCT, initial im-
aging with Gd-EOB-DTPA-MRI was less costly in all coun-
tries, except Korea and Spain, where the differences were 4 %
and 8 %, respectively. These results are explained by the sig-
nificant difference in the need for additional imaging proce-
dures (Fig. 3).
Cost of surgery
The results of the additional cost of surgery associated with
the three imaging strategies are also presented in Table 4. In
addition to the cost of the planned surgical procedure, the
consequences of each diagnostic strategy regarding surgery
were measured by two secondary outcomes: the costs accrued
by intra-operative modification of pre-operative surgical plans
and the costs of surgery where no resection was performed
(unnecessary surgery). The additional length of surgery due to
a modified surgical plan ranged from 20–120 min (median
45 min; mean 49 min). No resection was performed in three
patients who underwent surgery.
The cost of surgery was higher in the Gd-EOB-DTPA-MRI
group (as significantly more patients underwent surgery),















Fig. 2 Cost of diagnostic workup (ratio relative to Gd-EOB-DTPA-MRI)
per country. Please note that the transition probabilities and resource use
were always estimated for the pooled patient population, and not stratified
by country. Gd-EOB-DTPA-MRI gadoxetic-acid-enhanced MRI
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group. However, when the cost consequences (excluding the
cost of the planned surgery) were evaluated, initial imaging
with Gd-EOB-DTPA-MRI was less expensive than the strat-
egy starting with ECCM-MRI across all countries, but was
more expensive than starting with CE-MDCTacross all coun-
tries, except Sweden where starting with Gd-EOB-DTPA-
MRI was the least costly alternative (Table 4).
Sensitivity analysis and alternative scenarios
The results of the one-way sensitivity analysis and of three
alternative scenarios are presented in Tables 5 and 6.
Sensitivity analysis showed that the cost of liver surgery for
resected patients was the main driver for total cost. In the first
alternative scenario (‘No avoided surgery due to missing addi-
tional information of second imaging in the CE-MDCT group’),
if patients with missing information had not undergone the sec-
ond imaging and instead had unnecessary surgery, they would
have generated costs as depicted in Table 5.While the total costs
are still higher in the strategy startingwith Gd-EOB-DTPA-MRI
than starting with CE-MDCT, the difference decreased from €1,
036 to €465 per patient. In the second scenario (‘Unresectable
patients recognized before surgery’), the total cost difference
between Gd-EOB-DTPA-MRI and ECCM-MRI remained al-
most unchanged, whereas the difference between Gd-EOB-
DTPA-MRI and CE-MDCT decreased by approximately 6 %.
In the third scenario (‘Assumed that the probability for selection
for surgery was equal in all three groups’), the total cost differ-
ences between all three strategies were negligible.
Table 5 One-way sensitivity analysis of cost differences between Gd-EOB-DTPA-MRI and CE-MDCT (€ 2013), base case Germany





Cost of diagnostic workup + Cost
of modified/unnecessary surgery
Base case 1,036 922 114
CE −MDCT probability of further imaging −5 % 1,019 922 97
CE −MDCT probability of further imaging +5 % 1,053 922 131
CE −MDCT probability of modified surgery −5 % 1,037 922 115
CE −MDCT probability of modified surgery +5 % 1,036 922 114
Gd − EOB − DTPA −MRI probability of cancelled resection −5 % 1,033 922 111
Gd − EOB − DTPA −MRI probability of cancelled resection +5 % 1,039 922 117
Cost of Gd − EOB − DTPA −MRI − 5 % 1,024 922 102
Cost of Gd − EOB − DTPA −MRI +5 % 1,049 922 127
Cost of CE−MDCT −5 % 1,050 922 128
Cost of CE −MDCT +5 % 1,023 922 101
Cost of liver surgery, resected patients −5 % 990 876 114
Cost of liver surgery, resected patients +5 % 1,083 968 115
Cost of liver surgery, unresected patients −5 % 1,030 922 108
Cost of liver surgery, unresected patients +5 % 1,043 922 121
Cost of prolonged surgery −5 % 1,036 922 114
Cost of prolonged surgery +5 % 1,037 922 115
No avoided unnecessary surgery due to additional information of
second imaging in CE −MDCT group
465 1,006 −541
Unresectable patients recognized before surgery 972 987 −15
Same probability of surgery in each group* 32 −53 85
*Here the probability of being selected for surgery was 0.325 (32.5 %) in all arms since 115 patients out of 354 in the whole dataset were selected for
surgery
CE contrast-enhanced, CE-MDCT contrast-enhanced MDCT, ECCM-MRIMRI with extracellular contrast-media,Gd-EOB-DTPA-MRI gadoxetic-acid-
enhanced MRI, MRI magnetic resonance imaging, CT computed tomography, MDCT multiple detector CT
Fig. 3 Further imaging required, percentage of patients
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Discussion
This study analysed the cost impact of three different imaging
strategies (Gd-EOB-DTPA-MRI, ECCM-MRI, CE-MDCT)
in the evaluation of patients with confirmed or suspected
CRCLM. In almost all scenarios, the cost of diagnostic work-
up was lower when Gd-EOB-DTPA-MRI was used as the
initial imaging procedure compared with other strategies, de-
spite it being the more expensive imaging modality compared
with ECCM-MRI and CE-MDCT. This was due to the fact
that no patient in the Gd-EOB-DTPA-MRI group required
additional imaging for a treatment decision, compared to
18.1 % and 39.7 % of the safety population in the ECCM-
MRI and CE-MDCT groups, respectively.
Gd-EOB-DTPA-MRI as the initial imaging procedure re-
sulted in the detection of CRCLM in significantly more pa-
tients, offering more patients a more definitive assessment
and, in suitable candidates, potential curative treatment. This
result is in line with previous studies, which demonstrated the
superior sensitivity of Gd-EOB-DTPA-MRI to detect liver
metastasis [12–14, 21–23]. The observation that a higher per-
centage of patients in the group where Gd-EOB-DTPA-MRI
was the initial imaging procedure were assessed as eligible for
surgery, compared to the other two groups, was particularly
interesting. A possible explanation could be that the higher
confidence in the pre-operative imaging stimulated bolder
treatment decisions, especially regarding more aggressive sur-
gical approaches. Methodologically we can rule out a bias due
to the centrally organized randomization procedure as de-
scribed in the methods part as well as an improper randomi-
zation with regard to patients mean age, presence of non-
assessable lesions, number of affected segments, and total
number of lesions (Supplemental Table 3). Any unknown bi-
as, however, cannot be ruled out completely. Moreover, the
decisions regarding eligibility for surgery were made locally
in the centres and thus influenced by the local expertise.
Cost calculations must be considered in the context of the
relevant endpoints and interpreted with reference to the ulti-
mate goals of imaging in patients with CRCLM: sensitive
detection, accurate staging and correctly identifying patients
that can be offered potentially curative intervention.
Interestingly enough, the main driver of cost in our study
was not cost of imaging or contrast media, but cost of surgery.
As more patients in the Gd-EOB-DTPA-MRI group
Table 6 One-way sensitivity analysis of cost differences between Gd-EOB-DTPA-MRI and ECCM-MRI (€ 2013), base case Germany





Cost of diagnostic workup + Cost
of modified/unnecessary surgery
Base case 582 720 −138
ECCM −MRI probability of further imaging −5 % 607 720 −113
ECCM −MRI probability of further imaging +5 % 557 720 −163
ECCM −MRI probability of modified surgery −5 % 582 720 −138
ECCM −MRI probability of modified surgery +5 % 581 720 −139
Gd − EOB − DTPA −MRI probability of cancelled resection −5 % 579 720 −141
Gd − EOB − DTPA −MRI probability of cancelled resection +5 % 585 720 −135
Gd − EOB − DTPA −MRI −5 % 566 720 −154
Cost of Gd − EOB − DTPA −MRI +5 % 598 720 −122
Cost of ECCM −MRI −5 % 598 720 −122
Cost of ECCM −MRI +5 % 565 720 −155
Cost of liver surgery, resected patients −5 % 546 684 −138
Cost of liver surgery, resected patients +5 % 618 756 −138
Cost of liver surgery, unresected patients −5 % 589 720 −131
Cost of liver surgery, unresected patients +5 % 575 720 −145
Cost of prolonged surgery −5 % 582 720 −138
Cost of prolonged surgery +5 % 582 720 −138
Unresectable patients recognized before surgery 585 717 −132
Same probability of surgery in each group* −73 −72 −145
*Here the probability of being selected for surgery was 0.325 (32.5 %) in all groups since 115 patients out of 354 in the whole dataset were selected for
surgery
CE contrast-enhanced, CE-MDCT contrast-enhanced MDCT, ECCM-MRIMRI with extracellular contrast-media,Gd-EOB-DTPA-MRI gadoxetic-acid-
enhanced MRI, MRI magnetic resonance imaging, CT computed tomography, MDCT multiple detector CT
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underwent surgery, the total cost of surgery was higher in this
group. This fact should not be interpreted in the sense that Gd-
EOB-DTPA-MRI generates higher health-care costs, but that it
better fulfils the ultimate goals of imaging as mentioned above.
Even if patients cannot be operated on directly, but can be
resected only after a downsizing pre-operative chemotherapy,
the detailed knowledge of the initial findings seems to be of
high relevance to prevent local hepatic recurrences [21, 23].
The calculations were undertaken for several countries with
varied health-care systems and different levels of health re-
sources and spending, including resource-challenged coun-
tries, lending strength to the results. Furthermore, rather than
using protocol-defined clinical routines, regional differences
in the compilation of multidisciplinary treatment conference
teams were accounted for, making the findings more robust in
terms of real-life clinical practice. Although there were huge
differences in the reimbursement systems and unit costs, the
general outcome in the different countries was quite uniform.
From a patient perspective, the eligibility for surgery for
liver metastases represents a favourable event, changing often
from an initially assumed incurable situation to a potentially
curable situation, associated with a good chance of long-term
survival. From a hospital perspective, with reimbursement
systems in place in most countries, the higher costs are likely
to be covered by the higher revenue from the medical proce-
dures undertaken. Furthermore, from a health-care provider
perspective, the costs need to be weighed against the mid-
and long-term clinical and economic benefits of the potential-
ly life-preserving surgery. Potential advantages in the manage-
ment of surgical candidates may even increase the economic
benefit of a strategy starting with Gd-EOB-DTPA-MRI, as the
need for an additional imaging procedure after initial unequiv-
ocal imaging findings may defer some treatments.
The results of this study are consistent with results from a
previously published health economic model that was designed
to estimate the aggregated costs of three different imaging strat-
egies in patients with metachronous CRCLM [20]. In that study,
data collected from a Delphi panel composed of 13 pairs of
clinical experts using a decision-tree model, estimated probabil-
ities for the need of further imaging to come to a treatment
decision. Applying actual clinical data to themodel from diverse
clinical practices due to the multinational nature of the VALUE
trial, the performance of Gd-EOB-DTPA-MRI was better in the
clinical trial than predicted in the health economic model (actual
need for further imaging 0 % compared to 8.6 % in the model).
Specifically, the prediction that fewer examinations may lead to
cost savings in the strategy starting with Gd-EOB-DTPA-MRI
has been confirmed by the clinical study data.
The main limitation of this study was the lack of follow-up
of patients. The long-term clinical and economic impact of
each diagnostic strategy can therefore not be estimated. The
measurement of cost for the different imaging strategies go far
beyond the endpoints used in this paper. The performance of
the imaging is likely to affect health-care costs in patients until
the time of death or confirmation of a cure. For example, in
patients where curative intended treatment was initiated too
late due to a delay in diagnosis related to suboptimal imaging,
the cost of palliative measures has to be measured against the
cost of possible curative surgery. Likewise, tumour recurrence
as the result of suboptimal imaging in patients undergoing
curative-intended intervention will incur costs for both sur-
gery and palliative treatment, probably without any survival
advantage. It must, however, be emphasized that the cost for
individual patients in terms of suffering and premature death
due to failed therapeutic strategies as a result of sub-optimal
imaging is immeasurable.
In conclusion, the cost of the diagnostic work-up was sim-
ilar in all three arms, despite the fact that Gd-EOB-DTPA-
MRI is more expensive than ECCM-MRI and CE-MDCT,
due to the fact that patients randomized to Gd-EOB-DTPA-
MRI did not require additional imaging. The cost of surgery
was higher in the Gd-EOB-DTPA-MRI group, as significantly
more patients underwent surgery; however, this has to be
regarded in the sense that Gd-EOB-DTPA-MRI better fulfils
the ultimate goals of imaging to identify suitable patients for
liver surgery, thereby offering them a curative approach.
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